Conclusion of non-exclusive rebate agreements pursuant to Section 130a(8) of the German Social Code Book V for the specified active substances, with the possibility of joining under the so-called open-house procedure

Summary

The tender concerns a nationwide open-house procedure for non-exclusive rebate agreements for the active substance Omalizumab (R03DX05). Pharmaceutical companies can join on the same terms at any time until 31 December 2026, provided they request the participation documents, complete them in full and sign them. There are no individual contract negotiations and no exclusivity. Electronic invoicing is required.